Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026

Same author

Development of Genetically Modified ARH-77 Feeder Cells for Efficient Expansion of Natural Killer Cells with Potent Anti-Tumor Activity.

Cancers·2026

Same author

The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.

Haematologica·2026

Same author

Randomized Phase II Study of Bortezomib, Lenalidomide, and Dexamethasone (VRD) Versus Lenalidomide and Dexamethasone (RD) in Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM1910).

Cancer research and treatment·2026

Same author

Overcoming resistance in CD44-overexpressing myeloma through combination therapy with ATRA, bortezomib, and NK cells.

Cancer immunology, immunotherapy : CII·2026

Same author

Aerosolized Pentamidine Is an Effective Prophylaxis for <i>Pneumocystis jiroveci</i> Pneumonia in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation.

Journal of Korean medical science·2026

Same journal

Primary breast follicular lymphoma without a BCL2 rearrangement: insights into extranodal lymphoma biology.

Blood research·2026

Same journal

Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65-75 years: a real-world study.

Blood research·2026

Same journal

Novel treatment strategies in acute myeloid leukemia.

Blood research·2026

Same journal

Cross-cultural validation and reliability of the Korean version of the Haemophilia Activities List.

Blood research·2026

Same journal

Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention.

Blood research·2026

Same journal

Allogeneic stem cell transplantation for myelofibrosis in the modern era: Single-center outcomes with DIPSS risk stratification.

Blood research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 25, 2025

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Update on primary plasma cell leukemia.

Sung-Hoon Jung¹, Je-Jung Lee¹

¹Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.

|April 28, 2022

Summary

This summary is machine-generated.

Plasma cell leukemia (PCL), a rare aggressive cancer, has revised diagnostic criteria. Primary PCL, distinct from multiple myeloma, requires immediate intensive chemotherapy and stem cell transplant for better outcomes.

Keywords:

Diagnosis Plasma cell leukemia Treatment

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Experiment Videos

Last Updated: Sep 25, 2025

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Area of Science:

Hematology
Oncology
Clinical Medicine

Background:

Plasma cell leukemia (PCL) is a rare, aggressive plasma cell neoplasm.
It occurs in 0.5-4% of multiple myeloma (MM) patients.
Diagnostic criteria recently revised to ≥5% circulating plasma cells.

Purpose of the Study:

Review definitions and diagnostic criteria of PCL.
Describe clinical features of primary PCL.
Outline appropriate initial treatments for primary PCL.

Main Methods:

Review of recent literature on PCL.
Analysis of diagnostic criteria revisions.
Synthesis of clinical and treatment data for primary PCL.

Main Results:

PCL diagnosis now requires ≥5% circulating plasma cells.
Primary PCL presents differently from MM and has a poor prognosis.
Intensive chemotherapy and autologous stem cell transplantation are recommended.

Conclusions:

Primary PCL requires prompt, intensive treatment strategies.
Maintenance therapy post-transplant may prevent early relapse.
Understanding revised criteria is crucial for timely diagnosis and management.